500257 logo

Lupin Limited Stock Price

BSE:500257 Community·₹900.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

500257 Share Price Performance

₹1,970.30
-272.85 (-12.16%)
11.4% undervalued intrinsic discount
₹2,224.81
Fair Value
₹1,970.30
-272.85 (-12.16%)
11.4% undervalued intrinsic discount
₹2,224.81
Fair Value
Price ₹1,970.30
AnalystConsensusTarget ₹2,224.81

500257 Community Narratives

AnalystConsensusTarget·
Fair Value ₹2.22k 11.4% undervalued intrinsic discount

Emerging Markets And Chronic Therapies Will Expand Global Horizons

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative

Recent 500257 News & Updates

Lupin Limited Key Details

₹233.8b

Revenue

₹74.1b

Cost of Revenue

₹159.7b

Gross Profit

₹122.7b

Other Expenses

₹37.0b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
80.99
Gross Margin
68.31%
Net Profit Margin
15.83%
Debt/Equity Ratio
31.5%

Lupin Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Outstanding track record with flawless balance sheet and pays a dividend.

1 Risk
3 Rewards

About 500257

Founded
1968
Employees
24006
CEO
Vinita Gupta
WebsiteView website
www.lupin.com

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company also offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, women’s health, and central nervous system areas, as well as pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies. In addition, it focuses on various therapeutic spectrum, including rheumatology, oncology, neuroscience, and renal therapies. Further, the company is involved in the provision of diagnostics services, and digital healthcare services; and neuro rehabilition business. It operates through network consists of labs and collection centers. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

Indian Market Performance

  • 7 Days: 0.9%
  • 3 Months: 0.1%
  • 1 Year: -4.1%
  • Year to Date: 1.6%
In the last week, the market has stayed flat, however the Information Technology sector stood out, gaining 3.8%. The past year hasn't been profitable, with the market dropping 4.1%. As for the next few years, earnings are expected to grow by 16% per annum. Market details ›